Xilio Therapeutics (XLO) Research & Development (2020 - 2026)
Xilio Therapeutics (XLO) posted Research & Development of $19.8 million for Q1 2026, up 9.44% sequentially from $18.1 million in Q4 2025, and up 139.92% YoY from $8.3 million in Q1 2025.
Xilio Therapeutics (XLO) Research & Development (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Research & Development for 7 years, with the latest figure at $19.8 million in Q1 2026.
- Quarterly Research & Development rose 139.92% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.6 million (up 73.0% YoY) and the FY2025 annual result came in at $56.0 million, up 35.98% from the prior year.
- Research & Development grew to $19.8 million in Q1 2026 per XLO's latest filing, from $18.1 million in the prior quarter.
- Over five years, Research & Development peaked at $19.8 million in Q1 2026 and troughed at $8.3 million in Q1 2025.
- A 5-year average of $13.4 million and a median of $13.2 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2026: Research & Development tumbled 35.53% in 2024, then surged 139.92% in 2026.
- Over 5 years, Research & Development stood at $15.0 million in 2022, then fell by 21.74% to $11.7 million in 2023, then decreased by 24.71% to $8.8 million in 2024, then soared by 105.09% to $18.1 million in 2025, then climbed by 9.44% to $19.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $19.8 million, $18.1 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 14.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.56 Mn |
| Mar 31, 2026 | 19.83 Mn |
| Dec 31, 2025 | 18.12 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Jun 30, 2025 | 15.33 Mn |
| Mar 31, 2025 | 8.27 Mn |
| Dec 31, 2024 | 8.84 Mn |
| Sep 30, 2024 | 10.76 Mn |
| Jun 30, 2024 | 11.22 Mn |
| Mar 31, 2024 | 10.40 Mn |
| Dec 31, 2023 | 11.74 Mn |
| Sep 30, 2023 | 11.05 Mn |
| Jun 30, 2023 | 13.22 Mn |
| Mar 31, 2023 | 16.13 Mn |
| Dec 31, 2022 | 15.00 Mn |
| Sep 30, 2022 | 13.04 Mn |
| Jun 30, 2022 | 16.25 Mn |
| Mar 31, 2022 | 14.92 Mn |
| Dec 31, 2021 | 11.35 Mn |
| Sep 30, 2021 | 10.47 Mn |